Clinical Trials Detalhe
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
General Information
Gender
ALL
Age
from 40 Years to 90 Years
Phase
PHASE2
Study Type
INTERVENTIONAL
Location
Pfizer Investigational Site (Coimbra, Portugal)
Pfizer Investigational Site (Lisbon, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT00073476Summary
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Conditions
Stroke
Eligibility
Inclusion Criteria: Males \& females age 40-90 years Enrolled in study within 6 hours of onset of stroke symptoms Willing to sign informed consent form No significant disabilities prior to stroke Exclusion Criteria: Treatment with t-PA (tissue plasminogen activator) Premorbid modified rankin scale score of 2 or more